REFERENCES
- Düsterberg B, Ellman H, Müller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996; 10: 33–9
- Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 612-17, 672–7
- Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129–40
- Lidegaard L, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996; 53: 135–9
- Kuhl H. Comparative pharmacology of the newer progestogens. Drugs 1996; 51: 188–215
- Fotherby K, Caldwell A. New progestogens in oral contraception. Contraception 1994; 49: 1–32
- SperofFL, DeCherney A, the Advisory Board for New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993; 81: 1034–47
- Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995; 50: 364—95
- Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Phannacother 1995; 29: 736–42
- Kirkman RJ, Pedersen JH, Fioretti P, et al. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age. Contraception 1994; 49: 33–46
- Düsterberg B, Brill K. Clinical experience with a low-dose oral contraceptive containing gestodene. Adv Contracept 1990; 6(Suppl): 37–49
- Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 (lg ethinylestradiol/75 |Ig gestodene and 20 |ig ethinylestradiol/150 (ig desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52: 229–35
- Eyong E, Elstein M. Clinical update on a new progestogen - gestodene. Br J Fam Plana 1989; 15: 18–22
- Coenen CMH, Hollanders JMG, Rolland R, et al. The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. Eur J Contracept Reprod Health Care 1996; 1: 325–9
- Sullivan H, Furniss H, Elstein M. Effects of 21-day and 24-day oral contraceptive regimens containing gestodene (60 |ig) and ethinyl estradiol (15 (Ig) on ovarian activity. Fértil Steril 1999; 72: 115–20
- Ferenczy A. Anatomy and histology of the uterine corpus. In Kurman RJ, ed. Blaustein’s Pathology of the Female Genital Tract. New York: Springer Verlag, 1994: 327–66
- Hendrickson RM, Kempson RL. The uterine corpus. In Sternberg SS, ed. Diagnostic Surgical Pathology. New York: Raven Press, 1994; 52: 2091–193
- Gestodene Study Group 324. Comparison of the efficacy, safety, and cycle control of a 24-day regimen of gestodene 60 (ig/ethinylestradiol 15 (ig and a 21-day regimen of desogestrel/ethinylestradiol. Eur J Contracept Reprod Health Care 1999; 4 (Suppl 2): 17–25
- Gestodene Study Group 322. Open-label study of the contraceptive efficacy, safety, and cycle control of a 24-day regimen of gestodene 60 (ig/ethinylestradiol 15 |ig. Eur J Contracept Reprod Health Care 1999; 4 (Suppl 2): 9–15